Targeting the CSF1/CSF1R inhibitors has gained the most attention in this context with various approaches currently under clinical development for treatment of several cancer types including advanced castration-resistant prostate cancer (CRPC) with bone metastases (223). This evidence concerns the gene CSF1 and cancer.